Scanalytics wins Cisco award – BizTimes.com (Milwaukee)

Milwaukee-based startup Scanalytics Inc. has earned a top award from technology giant Cisco in an IoT for Business development competition.

Joe Scanlin and Matt McCoy founded Milwaukee startup Scanalytics.

Scanalytics, which developed smart flooring technology, earned a first place in the Best Smart Building technology category in the contest, which was held this month at Viva Technology 2017 in Paris. More than 5,000 startups and 68,000 people attended Viva Technology.

Scanalytics has developed a sensor-based engagement and analytics platform that monitors human behavior through foot traffic and predictive analytics. Among the uses the company has tested are retail product sales, in which a salesperson could be alerted if a customer is standing near a product, and business conferences, in which organizers can track booth traffic. The company deployed sensors to more than 100 clients globally in 2016.

Cisco and Scanalytics have now collaborated to create a new use for the smart flooring technology. Joe Scanlin, chief executive officer of Scanalytics, and Petr Bambasek, director of product, worked with Cisco engineers to link its technology to Ciscos Spark cloud collaboration program.

The team created a product through which a chat bot pulls data from Scanalytics application programming interface in real time, and communicates it to a buildings occupants via Spark. Among the potential uses was sending a reminder to employees to get up and move during the work day, and to inform building maintenance staff whether a bathroom needs cleaning based on usage.

We spend a majority of our lives indoors and these environments have a huge impact on everything from business efficiencies and productivity to our overall wellness, Scanlin said.Physical environments need to be properly equipped to capture, store and access information on how we interact with them, so they can operate like an autonomous nervous system and adjust themselves accordingly.

Milwaukee-based startup Scanalytics Inc. has earned a top award from technology giant Cisco in an IoT for Business development competition.

Joe Scanlin and Matt McCoy founded Milwaukee startup Scanalytics.

Scanalytics, which developed smart flooring technology, earned a first place in the Best Smart Building technology category in the contest, which was held this month at Viva Technology 2017 in Paris. More than 5,000 startups and 68,000 people attended Viva Technology.

Scanalytics has developed a sensor-based engagement and analytics platform that monitors human behavior through foot traffic and predictive analytics. Among the uses the company has tested are retail product sales, in which a salesperson could be alerted if a customer is standing near a product, and business conferences, in which organizers can track booth traffic. The company deployed sensors to more than 100 clients globally in 2016.

Cisco and Scanalytics have now collaborated to create a new use for the smart flooring technology. Joe Scanlin, chief executive officer of Scanalytics, and Petr Bambasek, director of product, worked with Cisco engineers to link its technology to Ciscos Spark cloud collaboration program.

The team created a product through which a chat bot pulls data from Scanalytics application programming interface in real time, and communicates it to a buildings occupants via Spark. Among the potential uses was sending a reminder to employees to get up and move during the work day, and to inform building maintenance staff whether a bathroom needs cleaning based on usage.

We spend a majority of our lives indoors and these environments have a huge impact on everything from business efficiencies and productivity to our overall wellness, Scanlin said.Physical environments need to be properly equipped to capture, store and access information on how we interact with them, so they can operate like an autonomous nervous system and adjust themselves accordingly.

See the rest here:
Scanalytics wins Cisco award - BizTimes.com (Milwaukee)

JPMorgan Checks In On Myriad Genetics Following 30% Rally – Benzinga

Myriad Genetics, Inc.'s (NASDAQ: MYGN) strong run has caught investors attentions, however, JPMorgan analyst Tycho Peterson still doesn't see the stock being able to offset a decline in the hereditary cancer business.

Peterson maintained his Underweight rating and $16 price target.

While in the past, the esoteric LDT market was viewed as sitting at the nexus of the secular shift in healthcare towards personalized medicine, this vision has, in our view, run up against the reality that the LDT business model has a number of challenges, with many labs attempting to support a pharma model centered around heavy rep counts without the benefit of patent protection, Peterson said.

While Peterson expects the stock to fall to $16 - it trades around $25.60 per share - he noted the stock could still move in either direction.

Myriad represents, in our view, a significant opportunity, given near-term catalysts that could drive the stock meaningfully higher or lower, with the setting of FY18 guidance during F4Q earnings (including forward expectations for hereditary cancer) being the most significant upcoming event post-UNH renewal, he said.

However, with its core business in (arguably) structural decline and pipeline that could be long on potential, but short on near-term financial impact, Myriad is not an easy company to value. While we believe the pipeline is intriguing, we do not believe that it can offset what we expect to be a continued steady decline in the core hereditary cancer business.

View More Analyst Ratings for MYGN View the Latest Analyst Ratings

Posted-In: JPMorgan Tycho PetersonAnalyst Color Reiteration Analyst Ratings

2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read more here:
JPMorgan Checks In On Myriad Genetics Following 30% Rally - Benzinga

After vote, Accelerated Genetics slated to merge – La Crosse Tribune

Accelerated Genetics and Select Sires Inc. will be a merged cooperative.

According to a news release, the merger follows a June 22 vote by Accelerate Genetics officials. The vote green-lights an agreement recommended by both companies boards of directors. The smaller Accelerated Genetics has reported financial difficulty in the past. The larger Ohio-based Select Sires will acquire Accelerated Genetics assets, including a bull farm in Westby.

Both companies specialize in artificial insemination of cattle. The companies have an established working relationship that started in 2001 when the companies allied in international markets.

Accelerated Genetics has been searching for a partner who could enhance the business and move it forward, said Scott Dahlk, Accelerated Genetics Board chairman. Joining forces with Select Sires is a positive move for both the member-owners and producers worldwide.

The company said Accelerated Genetics assets, employees and sales representatives will be integrated into the organization. Both companies operate under the cooperative-business model and share similar structures, according to the company.

By working together we will be stronger, said David Thorbahn, Select Sires president and chief executive officer. The value and expertise gained by joining the people from both organizations allow us to offer our customers a broader genetics program in addition to an outstanding animal health product line. Its very exciting to work together, enabling our organizations the ability to expand genetic research, technical support, service, and programs with people who are passionate about the dairy and beef industries.

Link:
After vote, Accelerated Genetics slated to merge - La Crosse Tribune

When Does Life Begin? Pro-Choice ‘Science’ Ignores the Facts. – National Review

When a human egg is fertilized, the result is never a newborn platypus. I didnt need four years of medical school, three years of pediatric residency, three years of neonatal fellowship, and close to two decades of medical practice to tell me that. In fact, high-school biology textbooks explain that all fertilized human eggs (zygotes), after approximately nine months, become newborn human babies unless something occurs to interrupt normal development.

This progression from fertilized egg to newborn is neither alternative science nor a rejection of long-standing medical knowledge. Yet in her paper Alternative Science and Human Reproduction, published this month in the New England Journal of Medicine, R. Alta Charo uses those labels to discredit anyone who acknowledges the biological truth about human development.

Charo attempts in her piece to discredit Donald Trumps pro-life executive-branch appointees. To this end, Charo, who is not a doctor, paints as ludicrous the claim that contraceptives can act as abortifacients by disrupting the natural process of pregnancy and ending a human life.

In reality, the progression of events from sexual intercourse to the creation of new human life is well established.

The process goes something like this: About six days after fertilization of the egg, and multiple cell divisions later, the zygote has become a cluster of cells (now called a morula). It has traversed the mothers fallopian tube and made its way into her uterus, where the process of implantation will then occur over the next four to five days. The various stages of development will continue to unfold until birth. Uterine implantation provides the ideal environmental mix for human development. If either a drug or a device disrupts implantation, the originating events that began approximately six days earlier are stopped, and the pregnancy is prevented from progressing.

So it follows that devices or medications that impede implantation effectively end or abort a pregnancy. This reality contradicts Charos argument that contraceptives abortifacient action is just a politically potent assertion by [Trump] appointees. The potency of the assertion derives from the fact that it is true. As Charo admits, one of the ways contraceptives work is to disrupt implantation.

The government and many physicians, however, define pregnancy as beginning only after implantation. As a physician myself, I prefer not to ignore the physical changes that occur between the moment fertilization occurs and implantation in the mothers womb. According to my embryology textbook, Before We Are Born: Essentials of Embryology and Birth Defects, the zygote represents the beginning of a human being.

From the moment of fertilization, the new human has unique DNA that serves as the cellular blueprint for the duration of his or her entire life. This medical fact does not depend on implantation: It depends entirely on the uniting of the parents DNA. Nor does this fact depend on an elected officials opinion or a lawyers or even a doctors opinion about when life begins.

Admittedly, zygotes dont look like humans. However, at the time of my grandmothers death, she didnt look much like her childhood pictures, and if we could have seen her as an embryo, she would have looked even less like the woman she developed into. But her DNA was intact at fertilization and remained intact throughout her life. My ability to recognize her at various stages of her life did not determine whether or not she was alive. The same is true for prenatal life and postnatal life.

There are multiple medical and legal papers arguing about when we should recognize life the moment we should acknowledge as the beginning of a life and what rights an individual does or does not have at different stages of life. Unfortunately, the arguments on these questions often reflect the ideological agenda of the arguer instead of the medical reality, which is that a unique life is created at fertilization. The distortion of this physiological truth, Charos article notwithstanding, is what makes human reproduction in our era the victim of alternative science.

READ MORE: Little-Known Facts about Roe v. Wade Planned Parenthoods Century of Brutality Planned Parenthoods Annual Report: Abortions Are Up, Prenatal Care Is Down

Robin Pierucci is a wife, a mother of three, and a practicing neonatologist. She is a member of Women Speak for Themselves.

Read the original post:
When Does Life Begin? Pro-Choice 'Science' Ignores the Facts. - National Review

ObsEva Announces Presentations Related to its Assisted … – GlobeNewswire (press release)

June 29, 2017 07:01 ET | Source: ObsEva SA

Phase 2 nolasiban previously reported data supports potential for meaningfully increasing live birth rates in ART

Non-clinical results of OBE022 for PTL demonstrate both monotherapy/combination potential

Geneva, Switzerland and Boston, MA - 29 June 2017 - ObsEva SA (Nasdaq: OBSV), a Swiss biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy, today announced it will make presentations at the European Society of Human Reproduction and Embryology (ESHRE) 2017 Annual Meeting, taking place July 2-5 in Geneva, Switzerland. These presentations will include the following:

"We are pleased to have the opportunity to present to the medical community, these two sets of data from the development programs of two of our product candidates, nolasiban and OBE022." said Ernest Loumaye, MD, PhD, OBGYN, CEO and Co-Founder of ObsEva.

"The results of the IMPLANT study with nolasiban, previously reported, show a potential absolute improvement of about 10 percent, or greater in live birth rate in women undergoing assisted reproduction for infertility. This magnitude of improvement, if replicated in our ongoing, 760 patients, Phase 3, IMPLANT-2 clinical trial that we began in March of 2017, could have a significant impact on patients undergoing IVF as currently only about one out of three patients will go home with a baby after an embryo transfer.

The pharmacology data presented for OBE022 are also important as they not only indicate the potential of our compound to treat preterm labor as monotherapy but also displays additive effects with currently available treatments that have limited efficacy. We are utilizing these key data to design the Phase 2 program for OBE022 in pregnant women with preterm labor, which is scheduled to begin later this year."

About Assisted Reproductive Technology

Infertility affects about 10 percent of reproductive-aged couples, with approximately 1.6 million ART treatments (including IVF and ICSI) performed worldwide each year.

While the success of ART depends on multiple factors such as embryo quality and ET procedure, a successful pregnancy ultimately hinges on the receptivity of the uterus to accept embryo implantation. Uterine contractions at the time of ET, as well as suboptimal thickness of the uterine wall and blood flow to the uterus, may impair the implantation of the embryo.

About Nolasiban

Nolasiban (previously known as OBE001), is an oral oxytocin receptor antagonist with the potential to decrease uterine contractions, improve uterine blood flow and enhance the receptivity of the endometrium to embryo implantation, all of which may increase the chance of successful pregnancy and live-birth among patients undergoing ART. ObsEva licensed nolasiban from Merck-Serono in 2013 and retains worldwide commercial rights.

About Preterm Labor

Preterm labor, defined as the birthing process starting prior to 37 weeks of gestation, is a serious condition characterized by uterine contractions, cervical dilation and rupture of the fetal membranes that can lead to preterm birth. According to a study published in the Lancet in 2012, approximately 15 million babies were born before 37 weeks of gestation in 2010, accounting for 11.1% of all live births worldwide. Over 1 million children under the age of five died in 2013 worldwide due to preterm birth complications, and many infants who survive preterm birth are at greater risk for cerebral palsy, delays in development, hearing and vision issues, and often face a lifetime of disability. The rates of preterm births are rising in almost all countries with reliable data for preterm birth, and are associated with an immense financial impact to the global healthcare system.

To date, only treatments with limited efficacy or restrictive safety issues are available to treat preterm labor. Inthe United States, recommended first-line tocolytic treatments (medications that inhibit labor) include beta-adrenergic receptor agonists, calcium channel blockers, or NSAIDs, which are used for short-term prolongation of pregnancy (up to 48 hours) to allow for the administration of antenatal steroids (e.g. betamethasone). Magnesium sulfate, used for fetal neuroprotection can also be used (up to 48 hours) to inhibit acute preterm labor. Approved tocolytic treatments inEuropeinclude beta-adrenergic agonists, which carry severe maternal cardiovascular risks, and intravenous infusions of atosiban (an oxytocin receptor antagonist).

While prostaglandin inhibitors (NSAIDs) have been shown to be effective for inhibiting preterm labor, use of such drugs is limited, due to the threat of serious and sometimes life-threatening side effects in the fetus. Such side effects may include kidney function impairment, premature constriction of the blood vessel connecting the pulmonary artery and the descending aorta in a developing fetus, and higher risk of thrombosis of the intestinal arteries (a condition called necrotizing enterocolitis).

About OBE022 andPGF2alpha

ObsEvais developing OBE022, a potential first-in-class, once daily, oral and selective prostaglandin F2alpha receptor antagonist, which is designed to control preterm labor by reducing inflammation, decreasing uterine contractions, preventing cervical changes and fetal membrane rupture without causing the potentially serious side effects to the fetus seen with non-specific prostaglandin inhibitors (NSAIDs). PGF2alpha is believed to induce contractions of the myometrium and also upregulate enzymes causing cervix dilation and membrane rupture. In nonclinical studies,ObsEvahas observed that OBE022 markedly reduces spontaneous and induced uterine contractions in pregnant rats without causing the fetal side effects seen with prostaglandin inhibitors such as indomethacin. ObsEva licensed OBE022 from Merck-Serono in 2015 and retains worldwide commercial rights.

About ObsEva

ObsEva is a clinical-stage biopharmaceutical company focused on the clinical development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids, preterm labor and improving ART outcomes. ObsEva is listed on The NASDAQ Global Select Market and is trading under the ticker symbol "OBSV". For more information, please visit http://www.ObsEva.com.

Cautionary Note Regarding Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as "believe", "expect", "may", "plan," "potential," "will," and similar expressions, and are based on ObsEva's current beliefs and expectations. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials and related interactions with regulatory bodies, ObsEva's reliance on third parties over which it may not always have full control, and other risks and uncertainties that are described in the Risk Factors section of ObsEva's Annual Report on Form 20-F for the year ended December 31, 2016, and other filings ObsEva makes with the SEC from time to time. These documents are available on the Investors page of ObsEva's website at http://www.obseva.com. Any forward-looking statements speak only as of the date of this press release and are based on information available to ObsEva as of the date of this release, and ObsEva assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.

###

Media Contact: Liz Bryan Spectrum Science lbryan@spectrumscience.com + 1 202-955-6222 x2526

Company Contact: CEO Office Contact Delphine Renaud delphine.renaud@obseva.ch +41 22-552-1550

Investor Contact Mario Corso Senior Director, Investor Relations mario.corso@obseva.com +1 781-366-5726

Attachments:

http://www.globenewswire.com/NewsRoom/AttachmentNg/0407f96e-505f-4b8f-a8df-6bd9c4023e6d

Related Articles

Visit link:
ObsEva Announces Presentations Related to its Assisted ... - GlobeNewswire (press release)

New research on spinal cord repair mechanism in fish can pave way for human spinal cord regeneration – Duke Chronicle

News By Nathan Luzum | Thursday, June 29 Courtesy of Wikimedia Commons

Zebrafish are model organisms to study because they have similargenetic structure to humans.

Zebrafish, a model organism already renowned for its regenerative abilities, has shown promise in yet another area of the fieldspinal regeneration.

Duke researchers discovered that when massive cushioning cells in the zebrafish notochorda precursor to the spine in vertebratesare damaged, another type of cell can find and replace the damaged ones. Because these cushioningor vacuolatedcells are similar betweenfish and humans, the discovery could yield clues with the potential tohelp victims of back or neck pain.

We saw that a cell type surrounding the giant cells moved in to the region of disruption and [was] actually able to replace the giant cells that had been compromised, restoring the notochord structure, wrote Jamie Garcia, graduate student in the School of Medicineand co-first author of the paper.

Michel Bagnat, senior author of the paper and associate professor of cell biology, likened the notochord to a tube. The outside of the notochord, orcasing of the tube, is composed of sheath cells, while the interior houses immense, egg-shaped vacuolated cells. These vacuolated cells account for the notochords ability to cushion and stretch.

However, Bagnat explained, the initial purpose of the research was not to identify a spinal repair mechanism, but rather to explain how the notochord can withstand such heavymechanical stress.

What you have is a very large cell, which is presumably fragile, that is subject to a lot of stress, he said. And then we ask, How is it keeping together?

They first concentrated on caveolaeminuscule pockets of the cell membraneas one possible explanation for the notochord's durability, and discovered that vacuolated cells lacking caveolae collapsed under heavy stress, ceasingto function properly.

We made mutants to basically disrupt [caveolae], and we were expecting that there would be some sort of disruption in these cells, which we found, Bagnat said.

The role of caveolae in the notochord matched the original hypothesis, but the research took an unexpected turnwhen the mutant zebrafish lacking proper caveolae ended up developing a fully formed spine.Bagnat explained that this was because the surrounding sheath cells differentiatedor transformedinto vacuolated cells. Somehow, the released contents of the damaged cell induced nearby sheath cells to replace the damaged structure.

The study is relevant to spinal degeneration in humans, as humans also possessvacuolated cells as shock-absorbing intervertebral discs. These discs can degenerate or become herniated, causing neck or back pain. However, according to the Mayfield Brain and Spine Clinic,nearly 30 percent of people without such pain also have some form of degeneration in intervertebral discs.

The disappearance of the giant vacuolated cells (which are conserved from fish to human) is often associated with degenerative disc disease, Garcia wrote. If we can understand how this basic regeneration process works in fish, we can better understand and possibly implement disc regeneration in humans who experience this condition.

Bagnat noted that a spinal repair mechanism is likely to exist in humans, but whether the process is the same as in zebrafish is unknown at this point.

If there was no repair mechanism, we would probably lose these vacuolated cells out of the center of the intervertebral disc very rapidly, Bagnat said. [However], in fact, we keep them for quite a long time.

Both Bagnat and Garcia explained that one of the labs interests is understanding how the sheath cells receive the necessary instructions to differentiate into a vacuolated cell. Bagnat suspected that the answer may lie in the contents released by a damaged vacuolated cell, sostudying this fluid could answer some major questions concerning disc repair.

If you understand the biology, perhaps you can keep the disc in better shape for a longer time, he said.

The Chronicle is your source for Duke news, sports, culture and dialogue.

Subscribe to the Chronicle: Newsletter | The Dirt | Overtime

Originally posted here:
New research on spinal cord repair mechanism in fish can pave way for human spinal cord regeneration - Duke Chronicle

Norris Cotton Cancer Center Announces New Chief From NY – Valley News

Lebanon Dartmouth-Hitchcock and Geisel School of Medicine at Dartmouth announced the hiring of a new leader for Norris Cotton Cancer Center in a release on Thursday.

Dr. Steven Leach, 57, a surgical oncologist, comes to Norris Cotton from the David M. Rubenstein Center for Pancreatic Cancer Research at Memorial Sloan Kettering Cancer Center in New York.

His new position will include overseeing cancer research at Dartmouth and the Geisel School of Medicine, as well as the cancer care that is provided throughout Dartmouth-Hitchcocks health system.

Both D-H and Dartmouth officials welcomed Leach in Thursdays release.

Dr. Leach is a world renowned pancreatic cancer specialist with significant interest in the biology, models, and mechanisms of cancer development and in genomic research to perform sequencing and analysis of the cell types involved in human pancreatic cancer, said Dr. James Weinstein, D-Hs outgoing chief executive.

He will lead Dartmouth-Hitchcock and the Cancer Center into a new era of research and discovery at the molecular level that will benefit patients for generations to come.

At Geisel, where Leach will hold the title of Preston T. and Virginia R. Kelsey Distinguished Chair in Cancer, the schools dean Dr. Duane Compton said, I look forward to working with (Leach) to grow our cancer-related research programs across Dartmouth and build on our outstanding cancer clinical care through Dartmouth-Hitchcock.

Leach will be the first permanent director of the center since former director Mark Israel left the post last fall. Chris Amos, the chairman of Geisels biomedical data science department, has served as interim director since October.

Leach was drawn to the position at Norris Cotton because of the opportunity to work throughout the region in with a multidisciplinary focus in collaboration with researchers at Geisel, D-H and Dartmouth College to push scientific envelopes, he said, in a phone interview on Thursday afternoon.

While hes in the midst of transitioning to the center, Leach said hes deeply involved in a crash course in all things Dartmouth ... issues and opportunities.

Leach comes to the job amid controversy about how funds raised for cancer research were spent. In October, Israel filed a lawsuit against Dartmouth-Hitchcock, alleging that he was ousted in an act of illegal retaliation after he objected to the diversion of $6 million raised for cancer research, including $1.6 million raised from The Prouty, Norris Cottons signature fundraising event.

D-H subsequently asked Grafton County Superior Court Judge Lawrence A. MacLeod Jr. to move the case to arbitration and, in April, MacLeod agreed. MacLeod has not yet ruled on a motion Israel filed last month seeking permission to file an amended suit.

Separately, Thomas Donovan, the director of the Charitable Trusts Unit in the New Hampshire Attorney Generals Office, concluded in January that D-H had not violated the law in 2015 when it spent money from donors on salary, equipment and occupancy costs associated with research.

And in February, cancer center officials announced in a Valley News op-ed a pledge that supporters donations will be used only for activities related to research and patient care, as well as governance guidelines written into a new agreement between D-H and Dartmouth College that clarify the authority of the centers director, who is a joint employee of both organizations.

For his part, Leach said he is aware of the issues relating to the way these funds were spent, but he has full confidence in the leadership of the two organizations moving forward.

Im confident in the leadership there that weve got everything in place, he said.

Leach himself is an enthusiastic fundraiser and he looks forward to connecting with people to tell the story of the wonderful science thats being done at Dartmouth.

(Its) something I really enjoy, he said.

Leach brings experiences as a researcher, teacher and clinician to the position.

He has served as the director for Sloan Ketterings pancreatic research center since it opened in 2014. He is also a professor of surgery at Weill Cornell Medical College of Cornell University.

Prior to coming to New York, Leach worked at Johns Hopkins University where he was a professor of pancreatic cancer research, surgery, oncology and cell biology, and chief of the division of surgical oncology.

At heart, Leach said he is a physician scientist, who began as a surgeon operating on all kinds of cancer patients and moved into research, teaching and administrative roles.

Leach holds a bachelors degree in biology from Princeton University and a medical degree from Emory University. He did a residency in general surgery and a post-doctoral research fellowship at Yale University, and a surgical oncology fellowship at the University of Texas MD Anderson Cancer Center.

He recently completed a term on Princetons board of trustees and serves as chairman of the Pancreatic Cancer Action Networks Scientific and Medical Advisory Board.

He expects to start the new position in September, but will be in the Upper Valley biking 50 miles in The Prouty on July 8.

Im looking forward to coming up and experiencing The Prouty, Leach said.

Nora Doyle-Burr can be reached at ndoyleburr@vnews.com or 603-727-3213.

Read the rest here:
Norris Cotton Cancer Center Announces New Chief From NY - Valley News

Scientists Manipulate ‘Signaling’ Molecules to Control Cell Migration – Bioscience Technology

Johns Hopkins researchers report they have uncovered a mechanism in amoebae that rapidly changes the way cells migrate by resetting their sensitivity to the naturally occurring internal signaling events that drive such movement. The finding, described in a report published online March 28 in Nature Cell Biology, demonstrates that the migratory behavior of cells may be less hard-wired than previously thought, the researchers say, and advances the future possibility of finding ways to manipulate and control some deadly forms of cell migration, including cancer metastasis.

"In different tissues inside the body, cells adopt different ways to migrate, based on their genetic profile and environment," says Yuchuan Miao, a graduate student at the Johns Hopkins University School of Medicine and lead author of the study. "This gives them better efficiency to perform specific tasks." For example, white blood cells rhythmically extend small protrusions that allow them to squeeze through blood vessels, whereas skin cells glide, like moving fans, to close wounds.

On the other hand, Miao notes, uncontrolled cell migration contributes to diseases, including cancer and atherosclerosis, the two leading causes of death in the United States. The migration of tumor cells to distant sites in the body, or metastasis, is what kills most cancer patients, and defective white blood cell migration causes atherosclerosis and inflammatory diseases, such as arthritis, which affects 54 million Americans and costs more than $125 billion annually in medical expenditures and lost earnings.

Because cells migrate in different ways, many drugs already designed to prevent migration work only narrowly and are rarely more than mildly effective, fueling the search for new strategies to control migratory switches and treat migration-related diseases, according to senior author Peter Devreotes, Ph.D., a professor and director of the Department of Cell Biology at the Johns Hopkins University School of Medicines Institute for Basic Biomedical Research.

People have thought that cells are typed by the way they look and migrate; our work shows that we can change the cell's migrating mode within minutes, adds Devreotes.

For the new study, Devreotes and his team focused on how chemical signaling molecules activate the motility machinery to generate protrusions, cellular feet that are a first step in migration. To do this, they engineered a strain of Dictyostelium discoideum, an amoeba that can move itself around in a manner similar to white blood cells. The engineered amoebae responded to the chemical rapamycin by rapidly moving the enzyme Inp54p to the cell surface, where it disrupted the signaling network. The cells also contained fluorescent proteins, or markers, that lit up and showed researchers when and where signaling molecules were at work.

Experiments showed that the engineered cells changed their migration behavior within minutes of Inp54p recruitment. Some cells, which the researchers termed oscillators, first extended protrusions all around the cell margins and then suddenly pulled them back again, moving in short spurts before repeating the cycle. Fluorescent markers showed that these cycles corresponded to alternating periods of total activation and inactivation, in contrast to the small bursts of activity seen in normal cells.

Other cells began to glide as fans, with a broad zone of protrusions marked by persistent signaling activity.

Devreotes describes the signaling behavior at the cell surface as a series of waves of activated signaling molecules that switch on the cellular motility machinery as they spread. In their normal state, cells spontaneously initiated signaling events to form short-lived waves that made small protrusions.

In contrast, oscillators had faster signaling waves that reached the entire cell boundary to generate protrusions before dying out. Fans also showed expanded waves that continually activated the cell front without ever reaching the cell rear, resulting in wide, persistent protrusions.

The scientists say their experiments show that the cell movement changes they saw resulted from lowering the threshold level of signaling activity required to form a wave. That is, cells with a lower threshold are more likely to generate waves and, once initiated, the activation signals spread farther with each step.

Devreotes says the teams experimental results offer what appears to be the first direct evidence that waves of signaling molecules drive migratory behavior. Previously, his laboratory showed a link between signaling and migration, but had not specifically examined waves.

In further experiments, Devreotes and his team found that they could recruit different proteins to shift cell motility, suggesting, he says, that altering threshold is a general cell property that can change behaviorno matter how cells migrate. His team was also able to restore normal motility to fans and oscillators by blocking various signaling activities, suggesting new targets for drugs that could be designed to control migration.

Devreotes cautions that what happens in an amoeba may not have an exact counterpart in a human cell, but studies in his lab suggest that something like the wave-signaling mechanism they uncovered operates in human cells as well.

The bottom line, says Miao, is that we now know we can change signaling wave behavior to control the types of protrusions cells make. When cells have different protrusions, they have different migratory modes. When we come to understand the essential differences between cells migratory modes, we should have better ways to control them during disease conditions.

Read more:
Scientists Manipulate 'Signaling' Molecules to Control Cell Migration - Bioscience Technology

Anatomy of a Goal: How Cristian Roldan’s defense, Clint Dempsey’s movement led to equalizer against Portland – SoundersFC.com

The Seattle Sounders stole a dramatic road point against the Portland Timbers last Sunday in what was their arguably their best effort of the season. Down a man and a goal for the entire second half, substitute Clint Dempsey headed home an equalizer in the 94th minute to stun Providence Park.

The entire sequence, though Roman Torres pinpoint cross to Dempsey, Dempseys towering header and the unlikeliest of goals did not matriculate from nothing. What led to the Sounders game-tying tally was a seemingly inconspicuousdefensive play by Cristian Roldan on Dairon Asprilla.

Nearing the end of the 93rd minute, the Timbers cleared the ball from their own 18-yard-box and found Asprilla in open space on the left side of the pitch. Desperate for an equalizer, the Sounders had thrown almost everyone forward, which in turnleft Asprilla and Fanendo Adi in a 2-on-2 situation with Nouhou and a retreating Roldan.

Rather than sprinting back aimlessly, Roldan defended with purpose, coming in goalside on an angle behind Asprilla.

When Asprilla finally receivedthe ball, his options were limited because of Roldans positioning. Asprilla turnedand facedbackward, attempting to hold up the ball in search of a teammate. He never gets the chance to find one.

Hanging on Asprillas right shoulder, Roldan reached his left leg around Asprilla and poked the ball away. Roldan then quickly led the Sounders back in the ascendancy and left an off-balanced Asprilla on the Providence Park turf.

What Roldans stalwart defending did was not only unbalance Asprilla, but the entire Portland team that had just begun pushing forward to clear its own end in anticipation ofan attack. Roldan recognizedthis and pickedout Osvaldo Alonso wide open in the center of the park.

The Timbers were scrambling at this point, but they were not totally undone until Dempsey set up his own attempt on goal with a simple off-the-ball run that very few players would have had the wherewithal to make.

Alonso hadthe ball and was looking for Dempsey to his right, but he was being trailed by Diego Chara with Ben Zemanski blocking Alonsos passing lane.

Rather than stay put or check back to Alonso, Dempsey saw a pocket of space behind Zemanski and to Zemanskisright. Dempsey ran toward it and by doing so, pulledChara out of position and forcedZemanski to lean in that direction, opening a giant passing lane for Alonso to find the late run ofTorres.

Another reason why Dempsey was able to able to rise and meet Torres cross without much resistance was becausehis run into the box was unimpeded. When the ball swungwide to Torres, Chara shifted his attentionand left Dempsey free to roam.

This left the two Timbers center backs with very little time to communicate on whose responsibility it was to guard Dempsey. By the time they figured it out, Dempsey was jumping over Amobi Okugo and redirecting Torres cross past a helpless Jake Gleeson in goal.

Dempseys finish was a fantastic one and is another example of why hes on the brink of becoming the United States all-time leading goalscorer, but it would not have happened without his subtle off-the-ball movement and a little help from the Swiss army knife that is Cristian Roldan. Goals dont happen in a vacuum. Singular moments of brilliance are always preceded by several small but vital plays, and the Sounders proved that yet again on Sunday.

View post:
Anatomy of a Goal: How Cristian Roldan's defense, Clint Dempsey's movement led to equalizer against Portland - SoundersFC.com

Inside Project Viking: Anatomy of deal to float AIB – Irish Times

Shortly after midnight last Friday, Ann Nolan, deputy head of the Department of Finance, and two officials working on AIBs flotation hailed a taxi from the Dawson Street base of stockbrokers Davy in Dublin to the home of Paschal Donohoe.

The Finance Minister of just one week had been on standby in Phibsborough all evening, as department officials, investment bankers from Deutsche Bank, Bank of America Merrill Lynch and Davy, divvied out AIB shares to more than 230 international fund managers and 6,500 small investors who had sought access to Europes largest initial public offering (IPO) so far this year.

The Minister made us a cup of tea and we spent an hour with him, said Des Carville, head of the Department of Finances banking unit and official in charge of the flotation, who shared the taxi ride. He had plenty of questions and we walked him through where we were with the deal and the final list of investors.

Armed with Mr Donohoes approval and signature on various documents, the trio headed back to the deals nerve centre in Davy, to finalise paperwork, paving the way for AIB to return that morning to the main stock markets in Dublin and London after a 7-year absence.

It was after 2am before all assembled, including AIB chief executive Bernard Byrne and his chief financial officer Mark Bourke, who had flown in from London that evening, headed home. They wouldnt get much sleep.

Project Viking, two years in the planning, culminated at 7am that morning when the Government confirmed it had sold an initial 25 per cent stake in the most expensive surviving Irish bank to bail out during the crisis, raising 3 billion. As the shares rose by as much as 7.7 per cent in early trading in Dublin, the investment banks underwriting the deal exercised an option to buy a further 3.8 per cent stake from the State and placed it on the market, raising a further 400 million for the exchequer.

The bank that floated was a very different animal to the one that was seized by the State two days before Christmas in 2010 to avert its collapse under the weight of mounting bad debts.

To limit its taxpayer bailout to 20.8 billion between 2009 and 2011, AIB was forced to sell billions of euros of assets including its profitable Polish unit, Bank Zachodni WBK, and 24 per cent stake in US lender M&T Bank and inflict 5 billion of losses on holders of its riskiest, subordinated bonds.

As a ward of the State, the company slashed thousands of jobs and put as many as 2,000 staff into a loan-restructuring unit to work through and restructure a mountain of soured loans, which topped 29 billion in 2013, over a third of its entire loan book at the time.

The fruits of the efforts were apparent in early March, when the group reported its impaired loans had fallen to 9 billion, pre-tax profits came to 1.7 billion for 2016 and that it had sufficient capital in reserve to give regulators comfort for AIB to pay a 250 million dividend.

The market reaction to the full-year 2016 results were very important we assessed it very closely, said Mr Carville. The icing on the cake was getting the dividend. That was very material in terms of AIBs valuation and also [potential investors in] the bank. Suddenly the guys who really like to have income in their investments were very interested in this as well.

While the then minister for finance, Michael Noonan, stuck to a script that he saw two windows to float AIB this year in May/June or in the autumn officials working on the deal were emboldened enough by the London reception and general market conditions to start working towards a deal in early May.

British prime minister Theresa Mays move on April 18th to call a snap election on June 8th put paid to such plans. An announcement on a deal was notionally put back until the end of the month, meaning it would price towards the end of June, leaving investors plenty of time to digest the UK vote.

But no one had counted on a second UK surprise, when it became clear in the early hours of June 9th that Theresa May had failed to return an expected landslide victory and now found herself short of a parliamentary majority 10 days before crucial Brexit talks were due to start.

As markets absorbed the shock outcome, AIBs chief executive, Mark Bourke popped out of his office at the banks headquarters in Ballsbridge in Dublin at 8am to meet Des Carville in a nearby coffee shop. Matters were out of their control at this stage, so they decided to keep a watching a brief on European markets.

At mid-morning, bankers from Deutsche Bank, Bank of America Merrill Lynch and Davy, who were leading the 3 billion share sale, as well as the Department of Finances independent advisers, Rothschild, gathered in Dublin for a pre-scheduled meeting on how the deal was going down.

While feedback from the nine firms working on the deal, including Citigroup, Goldman Sachs, Goodbody, JP Morgan, UBS and Investec and whose analysts had carried out 1,500 meetings with potential investors in less than two weeks, was upbeat, the UK result had thrown a spanner in the works.

By the time the markets had closed on Monday, advisers on the deal felt that issuance of the price range and prospectus could actually be brought forward. Michael Noonan made the call that evening to proceed immediately, setting an initial price range for the shares being sold at between 3.90 and 4.90 each. It would be his last major decision as finance minister, capping six years in office.

At AIB Bankcentre in Ballsbridge, a team in a fourth-floor room in the investor relations department where a wall carried four clocks displaying times in Dublin, Los Angeles, New York and Hong Kong kicked into action, mobilising three teams to market the bank globally.

Robert Mulhall, head of AIBs Irish retail and commercial banking division, was already on the west coast of the US, having attended a Google executive conference in Silicon Valley that weekend, according to sources. Group director of finance and investor relations Myles OGrady flew out to meet him on the Tuesday and begin that leg of the roadshow.

In Dublin, Bernard Byrne, Mark Bourke and investor relations managers Niamh Hore and Rose ODonovan kicked off in Dublin meeting fund managers before heading to London, where they were joined by group chief operating officer Tomas OMidheach.

Meanwhile, group treasurer Donal Galvin, chief economist Oliver Mangan and Janet McConkey of investor relations flew to Singapore to begin the courting of Asian investors before returning to Europe, where they met up with Colin Hunt, head of wholesale and institutional banking.

Within 24 hours of the initial pricing range being set, the investment banks decided to prod potential investors by putting out a notification that they had received enough orders to cover all the shares being sold.

On June 21st, Paschal Donohoe signed off on a narrowing of the price range to between 4.30 and 4.50, and the following morning he allowed managers of the transaction to send out a warning an hour before the order books closed at noon that any bids below 4.40 risked being cut out of the deal.

With the price of the transaction set at 4.40, the three main firms managing the process assembled at Davy at 5pm on June 22nd with Department of Finance officials, including Scott Rankin, Joseph Cummins, Ronan Heavey, Gary Hynds and Elaine McNamara and AIBs Bernard Byrne to go through the allocation of shares to investors.

Some 6,500 small investors would receive 10 per cent of the shares on offer. About 30 per cent of the institutional investors who sought to get on board were refused any shares as they hadnt met analysts or management during the process.

Wed never heard of them. The majority of them, if not all of them, were just momentum traders, who would sell immediately if the stock went up, said Mr Carville. It would have been close to midnight before the allocations were completed.

US investors snapped up a quarter of the shares being sold, with UK-based institutions accounting for a third, with the remainder handed out to investors across Europe and the rest of the world.

The reception in continental Europe wasnt quite as good as elsewhere, said an investment banking source close to the deal. There still is a bit of scepticism in Europe about Irish banks and, indeed, the banking sector in general.

While non-performing loans have come down sharply across Irish banks over the past four years, as the economy rebounded from the crash and lenders restructured problem loans at pace, almost 16 per cent of loans across the sector remain impaired, according to Government figures. Thats three times the European average.

Still, AIB shares jumped 4.5 per cent on the opening of trade in Dublin at 8am last Friday, to 4.60, before rising as much as 7.7 per cent.

Im absolutely satisfied that the 4.40 price was right, said Des Carville, a former corporate financier with Davy, who was hired by the department in 2013 to head the management of the States stakes in bailed-out banks. We lost quite a number of investors at that price, as it was just too expensive for them. Thats the acid test. But, importantly, we also kept equally high-quality investors at that level. But once you went above 4.40, the quality fell off a cliff. Mr Carvilles first congratulatory text of the day came within minutes of trading getting under way, from Richie Boucher, the outgoing chief executive of Bank of Ireland, in which taxpayers continue to own a 14 per cent stake.

He was followed shortly by Jeremy Masding, chief executive of Permanent TSB, which is 75 per cent State owned.

After that, it was around to Doheny & Nesbitts on Baggot Street for 18 members of the departments banking team for a quick celebratory breakfast.

Mr Byrne sent a short video message by email to AIBs 10,400 staff less than half the banks workforce before the crash shortly after 7am.

This marks a really satisfactory conclusion to what has been a long, difficult and complicated process, he said. Everyone should be very proud of what this investment means.

Now we are in a position where the bank that weve been building, the bank that weve asked everyone to believe in is clearly one that investors believe they can invest in.

Before the IPO, AIB had repaid only 3.3 billion of capital pumped into the bank. However, the State had also recouped an additional 3.5 billion in cash from AIB, the most costly bank rescue behind Anglo Irish Bank, by way of interest payments on bailout bonds and guarantee fees.

Mr Donohoe told journalists last week that he was confident the State would recover all of the money injected into the bank, over time. Still, by Michael Noonans previous admission, it could take up to a decade before taxpayers are fully rid of AIB shares.

Meanwhile, Nolan, a key figure on the States bailout and restructuring of the banking sector during the crisis, signalled yesterday she plans to retire at the end of next month

Continue reading here:
Inside Project Viking: Anatomy of deal to float AIB - Irish Times